U.S. FDA Grants Priority Review for Genentech's Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
September 11, 2026
September 11, 2026
SOUTH SAN FRANCISCO, California, Sept. 11 (TNSrep) -- Genentech, a member of the Roche Group, issued the following news release on Sept. 9, 2026:
* * *
U.S. FDA Grants Priority Review for Genentech's Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
* If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease)
* Filing acceptance . . .
* * *
U.S. FDA Grants Priority Review for Genentech's Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
* If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease)
* Filing acceptance . . .